HemaSphere
(Aug 2023)
P567: PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA
- Shaun Fleming,
- Gail Roboz,
- Amir T. Fathi,
- Tian Y. Zhang,
- Andrew Wei,
- Hetty Carraway,
- Leanne Holes,
- Erica Petrlik,
- Thomas Prebet,
- Daniel Lopes De Menezes,
- Iryna Bluemmert,
- Hao Sun,
- Farhad Ravandi
Affiliations
- Shaun Fleming
- 1 Alfred Hospital, Melbourne, Victoria, Australia
- Gail Roboz
- 2 Weill Cornell Medicine, New York, NY, United States
- Amir T. Fathi
- 3 Massachusetts General Hospital, Boston, MA, United States
- Tian Y. Zhang
- 4 Stanford University School of Medicine, Stanford, CA, United States
- Andrew Wei
- 5 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia
- Hetty Carraway
- 6 Cleveland Clinic, Cleveland, OH, United States
- Leanne Holes
- 7 Bristol Myers Squibb, Princeton, NJ, United States
- Erica Petrlik
- 7 Bristol Myers Squibb, Princeton, NJ, United States
- Thomas Prebet
- 8 Bristol Myers Squibb, Summit, NJ, United States
- Daniel Lopes De Menezes
- 9 Bristol Myers Squibb, San Francisco, CA, United States
- Iryna Bluemmert
- 10 Bristol Myers Squibb, Boudry, Switzerland
- Hao Sun
- 8 Bristol Myers Squibb, Summit, NJ, United States
- Farhad Ravandi
- 11 MD Anderson Cancer Center, Houston, TX, United States
- DOI
-
https://doi.org/10.1097/01.HS9.0000969172.27202.d1
- Journal volume & issue
-
Vol. 7
p.
e27202d1
WeChat QR code